Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2008-05-27
2008-05-27
Badio, Barbara P. (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S182000, C552S617000, C552S625000, C552S626000
Reexamination Certificate
active
07378404
ABSTRACT:
This invention describes the new 8β-substituted estratrienes of general formula I in which R2, R3, R6, R6′, R7, R7′, R9, R11, R11′, R12, R14, R15, R15′, R16, R16′, R17and R17′have the meanings that are indicated in the description, and R8means a straight-chain or branched-chain, optionally partially or completely halogenated alkyl or alkenyl radical with up to 5 carbon atoms, an ethinyl- or prop-1-inyl radical, as pharmaceutical active ingredients that have in vitro a higher affinity to estrogen receptor preparations of rat prostates than to estrogen receptor preparations of rat uteri and in vivo preferably a preferential action on bone rather than the uterus and/or a pronounced action with respect to stimulation of the expression of 5HT2a-receptors and 5HT2a-transporters, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds. The invention also describes the use of these compounds for treatment of estrogen-deficiency-induced diseases and conditions as well as the use of an 8β-substituted estratriene structural part in the total structures of compounds that have a dissociation in favor of their estrogenic action on bones rather than the uterus.
REFERENCES:
patent: 3681407 (1972-08-01), Los
patent: 3736345 (1973-05-01), Los
patent: 3806546 (1974-04-01), Los
patent: 4961931 (1990-10-01), Wong
patent: 4018828 (1990-12-01), None
patent: M2743 (1964-09-01), None
patent: 45004059 (1970-02-01), None
patent: 45004060 (1970-02-01), None
patent: 45004061 (1970-02-01), None
patent: 45024572 (1970-08-01), None
Database Chemabs ′Online!, Chemical Abstracts Service, Columbus, Ohio, US; Nagata, Wataru et al., “8. Beta. -Cyanoestanes derivatives,” retrieved from STN, Database accession No. 73:109984, XP002175034, abstract.
Database Chemabs ′Online!, Chemical Abstracts Service, Columbus, Ohio, US; Nagata, Wataru et al: “8.beta.-Methylestradiols,” retrieved from STN, Database accession No. 73:25750, XP002175035, abstract.
Database Chemabs ′Online!, Chemical Abstracts Service, Columbus, Ohio, US; Nagata, Wataru et al., “8.beta.-Methylestranes,” retrieved from STN, Database accession No. 73:25749, XP002175036, abstract.
Database Chemabs ′Online!, Chemical Abstracts Service, Columbus, Ohio, US; Nagata, Wataru et. al., “8.beta.-Methyl-9-dehydroestrone 3-ethers,” retrieved from STN, Database accession No. 73:25748, XP002175037, abstract.
Elger et al., “Novel oestrogen sulfamates: a new approach to oral hormone therapy,” Expert Opinion on Investigational Drugs, Apr. 1998, pp. 575-589, vol. 7, No. 4, XP002121926, ISSN: 1354-3784; p. 580-p. 581; tables 2-5, Ashley Publications Ltd., London, GB.
Fevig T L et al., “Estrogen receptor binding tolerance of 16-alpha-substituted estradiol derivatives,” Steroids: Structure, Function, and Regulation, 1988, pp. 471-498, vol. 51, No. 5-6, XP002159339, ISSN: 0039-128X; p. 485; example 3; table 1, Elsevier Science Publishers, New York, NY, US.
Database Biosis ′Online!, Biosciences Information Service, Philadelphia, PA, US; Fernandez A I et al., “Influence of hormonal status in relaxant effect of diethylstilbestrol and nifedipine on isolated rat uterus contraction,” 1995, Database accession No. PREV199598457779, XP002175038, abstract; & General Pharmacology, 1995, pp. 1281-1287, vol. 26, No. 6, ISSN: 0306-3623, abstract only.
Elger Walter
Fritzemeier Karl-Heinrich
Hegele-Hartung Christa
Hillisch Alexander
Kollenkirchen Uwe
Badio Barbara P.
Millen White Zelano & Branigan P.C.
Schering Aktiengesellschaft
LandOfFree
8β-hydrocarbyl-substituted estratrienes for use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 8β-hydrocarbyl-substituted estratrienes for use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 8β-hydrocarbyl-substituted estratrienes for use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2804241